New hope for rare blood vessel disease: upadacitinib shows promise
NCT ID NCT07500467
First seen Apr 13, 2026 · Last updated Apr 28, 2026 · Updated 4 times
Summary
This study looked at whether upadacitinib, a pill that targets inflammation, can help people with Takayasu arteritis that hasn't improved with standard treatments. The study included 12 adults with active disease. Researchers measured how many patients achieved complete or partial remission after 24 weeks of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TAKAYASU ARTERITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Rheumatology and Immunology, Peking University People's Hospital
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.